Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

Supplemental Digital Content is available in the text.

[1]  G. Filippatos,et al.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. , 2021, The New England journal of medicine.

[2]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[3]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[4]  L. Chu,et al.  Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. , 2021, Clinical therapeutics.

[5]  P. Ponikowski,et al.  Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure , 2021, European journal of heart failure.

[6]  P. Ponikowski,et al.  Universal Definition and Classification of Heart Failure. , 2021, Journal of cardiac failure.

[7]  K. Khunti,et al.  Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years , 2021, EClinicalMedicine.

[8]  K. Node,et al.  Letter by Tanaka and Node Regarding Article, "Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study". , 2021, Circulation. Cardiovascular quality and outcomes.

[9]  K. Petraki,et al.  Stochastic baryogenesis , 2020, Journal of Cosmology and Astroparticle Physics.

[10]  G. Bakris,et al.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.

[11]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[12]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[13]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[14]  G. D. Di Tanna,et al.  A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020) , 2020, PharmacoEconomics.

[15]  A. Banerjee,et al.  Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study , 2020, Diabetes, obesity & metabolism.

[16]  A. Deswal.  Heart Failure With Reduced Ejection Fraction and Renal Dysfunction: Beta-Blockers Do Not Disappoint. , 2019, Journal of the American College of Cardiology.

[17]  G. Filippatos,et al.  Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial , 2019, American Journal of Nephrology.

[18]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[19]  C. Ronco,et al.  Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. , 2019, Circulation.

[20]  F. Zannad,et al.  Cardiorenal Syndrome Revisited , 2018, Circulation.

[21]  G. Filippatos,et al.  Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[22]  Jacob P. Kelly,et al.  Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease , 2017, Journal of the American Heart Association.

[23]  R. Vettor,et al.  SGLT2 Inhibitors and the Diabetic Kidney , 2016, Diabetes Care.

[24]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[25]  Priyesh A. Patel,et al.  Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease , 2016, Circulation. Heart failure.

[26]  W. Paulus,et al.  Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation , 2016, European journal of heart failure.

[27]  K. Damman,et al.  The kidney in heart failure: an update. , 2015, European heart journal.

[28]  C. Lam.  Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction , 2015, Diabetes & vascular disease research.

[29]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[30]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[31]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[32]  G. Filippatos,et al.  Renal dysfunction and heart failure: things are seldom what they seem. , 2014, European heart journal.

[33]  P. Ponikowski,et al.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.

[34]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[35]  W. Tang,et al.  Cardiorenal Syndrome Revisited , 2013 .

[36]  R. Mehrotra,et al.  Cardiovascular disease in chronic kidney disease , 2012 .

[37]  Youhua Liu.  Cellular and molecular mechanisms of renal fibrosis , 2011, Nature Reviews Nephrology.

[38]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[39]  P. McNulty,et al.  Diabetes mellitus and heart failure. , 2003, Congestive heart failure.

[40]  J. Toman,et al.  [Acute and chronic heart failure]. , 1997, Vnitrni lekarstvi.